What can exome sequencing do for you?
- Jacek Majewski1,2,
- Jeremy Schwartzentruber1,
- Emilie Lalonde1,2,
- Alexandre Montpetit1,
- Nada Jabado2,3
- 1McGill University and Genome Quebec Innovation Centre, Montreal, Canada
- 2Department of Human Genetics, McGill University, Montreal, Canada
- 3Department of Pediatrics, McGill University Health Center Research Institute, Montreal, Canada
- Correspondence to Dr Nada Jabado, Montreal Children's Hospital Research Institute, 4060 Ste Catherine West, PT-239, Montreal, Quebec H3Z 2Z3, Canada;
Contributors All authors contributed to the design and writing of this manuscript.
- Received 29 May 2011
- Accepted 6 June 2011
- Published Online First 5 July 2011
Recent advances in next-generation sequencing technologies have brought a paradigm shift in how medical researchers investigate both rare and common human disorders. The ability cost-effectively to generate genome-wide sequencing data with deep coverage in a short time frame is replacing approaches that focus on specific regions for gene discovery and clinical testing. While whole genome sequencing remains prohibitively expensive for most applications, exome sequencing—a technique which focuses on only the protein-coding portion of the genome—places many advantages of the emerging technologies into researchers' hands. Recent successes using this technology have uncovered genetic defects with a limited number of probands regardless of shared genetic heritage, and are changing our approach to Mendelian disorders where soon all causative variants, genes and their relation to phenotype will be uncovered. The expectation is that, in the very near future, this technology will enable us to identify all the variants in an individual's personal genome and, in particular, clinically relevant alleles. Beyond this, whole genome sequencing is also expected to bring a major shift in clinical practice in terms of diagnosis and understanding of diseases, ultimately enabling personalised medicine based on one's genome. This paper provides an overview of the current and future use of next generation sequencing as it relates to whole exome sequencing in human disease by focusing on the technical capabilities, limitations and ethical issues associated with this technology in the field of genetics and human disease.
Funding This work was supported by the McGill University Health Center Research Institute. NJ is the recipient of a Chercheur Boursier award from Fonds de Recherche en Santé du Quebec. JM is a recipient of a Canada Research Chair. EL is funded by the Canadian Institute for Health Research.
Competing interests None.
Patient consent Obtained.
Provenance and peer review Not commissioned; internally peer reviewed.